13 hours Ago By ABMN Staff
Marshall Wace LLP reduced its holdings in Janux Therapeutics, Inc. ( NASDAQ:JANX – Free Report ) by 53.5% during the 4th quarter, Holdings Channel reports.
The fund owned 22,348 shares of the company’s stock after selling 25,703 shares during the quarter. Marshall Wace LLP’s holdings in Janux Therapeutics were worth $1,197,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also modified their holdings of the business.
Russell Investments Group Ltd. boosted its holdings in shares of Janux Therapeutics by 77.7% in the 4th quarter.
Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after acquiring an additional 442 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Janux Therapeutics by 1.
6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after acquiring an additional 599 shares in the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 7.
9% in the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after acquiring an additional 928 shares in the last quarter. China Universal Asset Management Co.
Ltd. boosted its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter.
China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after acquiring an additional 1,095 shares in the last quarter.
Finally, Virtu Financial LLC boosted its holdings in shares of Janux Therapeutics by 17.5% in the 4th quarter. Virtu Financial LLC now owns 8,769 shares of the company’s stock worth $469,000 after acquiring an additional 1,306 shares in the last quarter.
75.39% of the stock is owned by institutional investors and hedge funds. Insiders Place Their Bets In other Janux Therapeutics news, Director Ra Capital Management, L.
P. acquired 110,206 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $31.
02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company’s stock, valued at approximately $314,582,722.
74. This trade represents a 1.10 % increase in their position.
The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $30.
00, for a total value of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at $2,464,170.
This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here .
Over the last quarter, insiders have sold 10,002 shares of company stock worth $348,203. Insiders own 29.40% of the company’s stock.
Janux Therapeutics Trading Up 1.0 % Janux Therapeutics ( NASDAQ:JANX – Get Free Report ) last issued its earnings results on Thursday, February 27th. The company reported ($0.
36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13.
Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.
As a group, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.
Analysts Set New Price Targets Several brokerages have recently commented on JANX. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd.
William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective (up previously from $75.
00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Scotiabank reduced their price objective on Janux Therapeutics from $62.00 to $41.
00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and a consensus price target of $95.
25. Check Out Our Latest Research Report on Janux Therapeutics About Janux Therapeutics ( Free Report ) Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Further Reading Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. ( NASDAQ:JANX – Free Report ).
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
